Solid Biosciences to Present at JMP Securities Life Sciences Conference
08 Maio 2023 - 5:05PM
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company
developing genetic medicines for neuromuscular and cardiac
diseases, today announced that Bo Cumbo, President and Chief
Executive Officer, will present at the JMP Securities Life Sciences
Conference on Monday, May 15, 2023 at 1:00 PM ET.
A live webcast of the presentation will be
available on the Events page of the Investors section of the
Company website or by clicking here. A webcast replay will be
archived for 30 days on the Events page.
Institutional investors interested in meeting
with management during the conference may reach out to their JMP
Securities representative.
About Solid BiosciencesSolid
Biosciences is a life science company focused on advancing a
portfolio of neuromuscular and cardiac programs, including SGT-003,
a differentiated gene transfer candidate for the treatment of
Duchenne, AVB-202-TT, a gene transfer candidate for the treatment
of Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated
cardiomyopathy, and additional assets for the treatment of
undisclosed cardiac diseases. Solid aims to be the center of
excellence, bringing together those with expertise in science,
technology, disease management and care. Patient-focused and
founded by those directly impacted by Duchenne, Solid’s mandate is
to improve the daily lives of patients living with these
devastating diseases. For more information, please visit
www.solidbio.com.
Solid Biosciences Investor Contact:Leah
MonteiroVP of Investor Relations &
Communications617-821-4427lmonteiro@solidbio.com
Solid Biosciences Media Contact:Tim
PalmerAssociate Director, Corporate Communications
607-760-4223Tim@solidbio.com
Solid Biosciences (NASDAQ:SLDB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Solid Biosciences (NASDAQ:SLDB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024